The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype 1b-infected patients with cirrhosis is still under debate. Our primary endpoint was to compare the sustained virological response at post-treatment week 12 (SVR12) of sofosbuvir-ledipasvir in combination with ribavirin for 12 weeks, and sofosbuvir-ledipasvir alone for 24 weeks. This was a prospective observational study that enrolled 424 (195 naive, 229 experienced; 164 treated for 12 weeks with Ribavirin and 260 with sofosbuvir-ledipasvir alone for 24 weeks) consecutive HCV genotype 1b-infected patients with cirrhosis. The SVR12 rates were 93.9% and 99.2% in patients treated for 12 and 24 weeks, respectively (P = .002). The baseline charact...
Background & aimsWe report data from two similarly designed studies that evaluated the efficacy,...
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to t...
Treatment of hepatitis C virus (HCV) infection with ledipas-vir/sofosbuvir promises tremendous benef...
The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype...
BACKGROUND & AIMS:We aimed to evaluate the safety and effectiveness of 12 or 24 weeks treatment ...
BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting...
International audiencePatients with cirrhosis resulting from chronic hepatitis C virus (HCV) infecti...
Background & aimsThe combination of ledipasvir and sofosbuvir has been approved for treatment of...
Background: Treatment options are limited for patients infected by hepatitis C virus (HCV) with adva...
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C ...
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase...
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase...
International audienceBackgroundIn phase 2 studies, treatment with the all-oral combination of the n...
Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who hav...
BACKGROUND Treatment options are limited for patients infected by hepatitis C virus (HCV) with ad...
Background & aimsWe report data from two similarly designed studies that evaluated the efficacy,...
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to t...
Treatment of hepatitis C virus (HCV) infection with ledipas-vir/sofosbuvir promises tremendous benef...
The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype...
BACKGROUND & AIMS:We aimed to evaluate the safety and effectiveness of 12 or 24 weeks treatment ...
BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting...
International audiencePatients with cirrhosis resulting from chronic hepatitis C virus (HCV) infecti...
Background & aimsThe combination of ledipasvir and sofosbuvir has been approved for treatment of...
Background: Treatment options are limited for patients infected by hepatitis C virus (HCV) with adva...
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C ...
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase...
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase...
International audienceBackgroundIn phase 2 studies, treatment with the all-oral combination of the n...
Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who hav...
BACKGROUND Treatment options are limited for patients infected by hepatitis C virus (HCV) with ad...
Background & aimsWe report data from two similarly designed studies that evaluated the efficacy,...
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to t...
Treatment of hepatitis C virus (HCV) infection with ledipas-vir/sofosbuvir promises tremendous benef...